OTC: HLUBF - H. Lundbeck A/S

Rentabilité sur six mois: -27.38%
Rendement en dividendes: +16.83%
Secteur: Healthcare

Calendrier des promotions H. Lundbeck A/S

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

plus de détails
It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 16.83
Дивиденд ао 0.7
Сайт https://www.lundbeck.com
Цена ао 4.43
Changement de prix par jour: 0% (4.43)
Changement de prix par semaine: 0% (4.43)
Changement de prix par mois: 0% (4.43)
Changement de prix sur 3 mois: -15.09% (5.2175)
Changement de prix sur six mois: -27.38% (6.1)
Changement de prix par an: +3.87% (4.265)
Evolution du prix sur 3 ans: 0% (4.43)
Evolution du prix sur 5 ans: 0% (4.43)
Evolution des prix sur 10 ans: 0% (4.43)
Evolution des prix depuis le début de l'année: -15.62% (5.25)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 1.39 9
P/BV 0.1858 10
P/E 12.08 8
EV/EBITDA 4.3 10
Total: 9.38

Efficacité

Nom Signification Grade
ROA, % 0.9065 1
ROE, % 1.54 1
Total: 2.5

Dividendes

Nom Signification Grade
Div yield, % 16.83 10
DSI 1 10
Total: 8.41

Devoir

Nom Signification Grade
Debt/EBITDA 5.05 0
Total: 6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -83.42 0
Rentabilité Ebitda, % -81.03 0
Rentabilité EPS, % -97.51 0
Total: 1.6
Plus de détails

Établissements Volume Partager, %
Vanguard International Stock Index-Total Intl Stock Indx 766645 0.38
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 448123 0.23
iShares Core MSCI EAFE ETF 373578 0.19
DFA International Small Cap Value Portfolio 233923 0.12
iShares MSCI EAFE Small Cap ETF 208316 0.1
Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Index Fund 124308 0.06
Vanguard International Stock Index-Vanguard European Stock Index 124066 0.06
iShares Core MSCI Total International Stock ETF 96483 0.05
Dimensional ETF Tr-Dimensional International Small Cap Value ETF 80813 0.04
iShares MSCI Denmark ETF 77939 0.04



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Joerg Hornstein CFO & Executive VP of Corporate Functions 1.23M 1977 (48 années)
Mr. Lars Bang Executive Vice President of Product Development & Supply 1.14M 1962 (63 année)
Dr. Per Johan Luthman Executive Vice President of Research & Development 1.27M 1959 (66 années)
Mr. Charl van Zyl President & CEO 5.34M 1967 (58 années)
Dr. Tarek Samad Ph.D. Senior VP & Head of Research N/A
Mr. Palle Holm Olesen Chief Specialist & VP of Investor Relations N/A
Mr. Ole Chrintz Senior Vice President of International Markets N/A 1958 (67 années)
Dr. Rupert Sandbrink M.D., Ph.D. Senior VP & Head of Clinical Development N/A 1964 (61 année)
Ms. Tine Ostergaard Hansen Senior Vice President of Corporate Communications & Public Affairs N/A 1975 (50 années)
Ms. Dianne Holto Executive Vice President of People & Culture 1973 (52 année)

Adresse: Denmark, Valby, Ottiliavej 9 - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.lundbeck.com